PE20120592A1 - Metodo con biomarcadores para el seguimiento de un tratamiento - Google Patents

Metodo con biomarcadores para el seguimiento de un tratamiento

Info

Publication number
PE20120592A1
PE20120592A1 PE2011001619A PE2011001619A PE20120592A1 PE 20120592 A1 PE20120592 A1 PE 20120592A1 PE 2011001619 A PE2011001619 A PE 2011001619A PE 2011001619 A PE2011001619 A PE 2011001619A PE 20120592 A1 PE20120592 A1 PE 20120592A1
Authority
PE
Peru
Prior art keywords
treatment
disease
biomarker
biomarkers
monitoring
Prior art date
Application number
PE2011001619A
Other languages
English (en)
Inventor
Tokuzo Arao
Kanae Kudo
Kazuhiko Nakagawa
Kazuto Nishio
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42129920&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20120592(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of PE20120592A1 publication Critical patent/PE20120592A1/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5064—Endothelial cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Abstract

REFERIDA A UN METODO O SISTEMA PARA EL SEGUIMIENTO DE UN TRATAMIENTO IMPLICADO CON LA PROLIFERACION CELULAR, CON LA SAL MONOETANOSULFONATO DE 3-Z-[1-(4-(N-((4-METIL-PIPERAZIN-1-IL)-METILCARBONIL)-N-METILAMINO)-ANILINO)-1-FENIL-METILEN]-6-METOXICARBONIL-2-INDOLINONA QUE COMPRENDE DETERMINAR SI UNA MUESTRA DE SANGRE COMPRENDE UN BIOMARCADOR EN UNA CANTIDAD QUE ES INDICATIVA PARA DICHO TRATAMIENTO. DICHO BIOMARCADOR INDICA UN CAMBIO EN LA EXPRESION O ESTADO DE UNA PROTEINA O EN LA CANTIDAD DE CELULAS ESPECIFICAS QUE SE CORRELACIONA CON EL RIESGO O PROGRESION DE UNA ENFERMEDAD O CON LA SUSCEPTIBILIDAD DE LA ENFERMEDAD A UN TRATAMIENTO DADO. REFERIDA ADEMAS A UN KIT DE DIAGNOSTICO QUE COMPRENDE EL MEDIO PARA REALIZAR DICHO METODO
PE2011001619A 2009-03-12 2010-03-11 Metodo con biomarcadores para el seguimiento de un tratamiento PE20120592A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09154964 2009-03-12

Publications (1)

Publication Number Publication Date
PE20120592A1 true PE20120592A1 (es) 2012-06-09

Family

ID=42129920

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011001619A PE20120592A1 (es) 2009-03-12 2010-03-11 Metodo con biomarcadores para el seguimiento de un tratamiento

Country Status (24)

Country Link
US (1) US8802384B2 (es)
EP (1) EP2406628A1 (es)
JP (1) JP5667581B2 (es)
KR (1) KR20110137307A (es)
CN (1) CN102334030A (es)
AR (1) AR076113A1 (es)
AU (1) AU2010223256B2 (es)
BR (1) BRPI1011688A2 (es)
CA (1) CA2755055A1 (es)
CL (1) CL2011002260A1 (es)
CO (1) CO6430497A2 (es)
EA (1) EA201101300A1 (es)
EC (1) ECSP11011323A (es)
IL (1) IL214747A0 (es)
MA (1) MA33120B1 (es)
MX (1) MX2011009482A (es)
NZ (1) NZ594843A (es)
PE (1) PE20120592A1 (es)
SG (1) SG174324A1 (es)
TN (1) TN2011000457A1 (es)
TW (1) TW201100802A (es)
UA (1) UA107789C2 (es)
UY (1) UY32482A (es)
WO (1) WO2010103058A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2299987T (lt) * 2008-06-06 2018-05-25 Boehringer Ingelheim International Gmbh Farmacinės vaisto formos kapsulė, apimanti indolinono darinio suspensijos kompoziciją
UA107560C2 (uk) * 2008-06-06 2015-01-26 Фармацевтична лікарська форма для негайного вивільнення похідної індолінону
US20170065529A1 (en) 2015-09-09 2017-03-09 Boehringer Ingelheim International Gmbh Pharmaceutical dosage form for immediate release of an indolinone derivative
US20140350022A1 (en) 2013-05-10 2014-11-27 Boehringer Ingelheim International Gmbh Efficacious treatment of NSCLC and predictive clinical marker of the responsiveness of a tumour to a treatment
CN104003925B (zh) * 2013-06-05 2016-03-30 四川大学 吲哚酮化合物或其衍生物及其用途
WO2018081236A1 (en) * 2016-10-28 2018-05-03 Cedars-Sinai Medical Center Method of predicting progression of idiopathic pulmonary fibrosis and monitoring of therapeutic efficacy

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6762180B1 (en) * 1999-10-13 2004-07-13 Boehringer Ingelheim Pharma Kg Substituted indolines which inhibit receptor tyrosine kinases
UA75054C2 (uk) 1999-10-13 2006-03-15 Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг Заміщені в положенні 6 індолінони, їх одержання та їх застосування як лікарського засобу
DE10233500A1 (de) * 2002-07-24 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-Monoethansulfonat und dessen Verwendung als Arzneimittel
US20040204458A1 (en) 2002-08-16 2004-10-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of Lck inhibitors for treatment of immunologic diseases
DE10237423A1 (de) 2002-08-16 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von LCK-Inhibitoren für die Behandlung von immunologischen Erkrankungen
US20050043233A1 (en) * 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
EP1571225A1 (en) 2004-03-02 2005-09-07 PrimaGen Holding B.V. Diagnosis of a disease and monitoring of therapy using the AC133 gene
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
EP1777523A1 (en) 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
US8557531B2 (en) 2006-04-18 2013-10-15 Wellstat Biologics Corporation Detection of circulating endothelial cells
EP1870400A1 (en) 2006-06-08 2007-12-26 Boehringer Ingelheim Pharma GmbH & Co. KG Salts and crystalline salt forms of an 2-indolinone derivative
MX2009002471A (es) * 2006-09-07 2009-03-20 Astrazeneca Ab Metodo para evaluar a pacientes para tratamiento con farmacos que detectan la transfeccion durante el redondeamiento (ret) de tirosina cinasa receptora.
JP2010524003A (ja) 2007-04-13 2010-07-15 ブリストル−マイヤーズ スクイブ カンパニー 血管内皮増殖因子受容体−２モジュレーターに対する感受性を決定するためのバイオマーカーおよび方法
US20100184049A1 (en) 2007-04-27 2010-07-22 Steve Goodison Glycoprotein Profiling of Bladder Cancer

Also Published As

Publication number Publication date
ECSP11011323A (es) 2011-10-31
CL2011002260A1 (es) 2012-03-23
US20100233705A1 (en) 2010-09-16
KR20110137307A (ko) 2011-12-22
BRPI1011688A2 (pt) 2016-03-22
EA201101300A1 (ru) 2012-04-30
CO6430497A2 (es) 2012-04-30
UA107789C2 (en) 2015-02-25
MX2011009482A (es) 2011-09-27
US8802384B2 (en) 2014-08-12
UY32482A (es) 2010-10-29
CA2755055A1 (en) 2010-09-16
JP2012520446A (ja) 2012-09-06
TN2011000457A1 (en) 2013-03-27
WO2010103058A1 (en) 2010-09-16
JP5667581B2 (ja) 2015-02-12
AU2010223256A1 (en) 2011-09-15
AR076113A1 (es) 2011-05-18
TW201100802A (en) 2011-01-01
MA33120B1 (fr) 2012-03-01
IL214747A0 (en) 2011-11-30
CN102334030A (zh) 2012-01-25
EP2406628A1 (en) 2012-01-18
AU2010223256B2 (en) 2014-08-21
NZ594843A (en) 2014-03-28
SG174324A1 (en) 2011-10-28

Similar Documents

Publication Publication Date Title
MX337666B (es) Ensayos regulados mediante proximidad para detectar proteinas de fusion oncogenicas.
ATE554389T1 (de) Apex als marker für lungenkrebs
PE20120592A1 (es) Metodo con biomarcadores para el seguimiento de un tratamiento
BR112014031365A2 (pt) métodos de detectar doenças ou condições
ES2570731T3 (es) Método de detección de cáncer
HK1115636A1 (en) Use of cyfra 21-1 as a marker for colorectal cancer cyfra 21-1
CR20110567A (es) Dispositivos para diagnostico y metodos relacionados
MA34263B1 (fr) Marqueurs de prédiction utiles dans traitement du syndrome de l'x fragile (fxs)
BRPI0915619A2 (pt) métodos para determinar uma probabilidade de que um sujeito tenha contribuído com material genético para amostra de teste de material genético, para caracterizar amostra de teste de material genético e para determinar se uma pessoa de interesse contribuiu com material genético para uma amostra de teste de material genético, kit para análise de amostra de teste de material genético e sistema para determinar se um sujeito contribuiu com material genético para uma amostra
GB2467704A (en) Methods of monitoring conditions by sequence analysis
ATE508364T1 (de) Diagnoseverfahren für präeklampsie
EA201370063A1 (ru) Фосфолипидом рака
EA201391627A1 (ru) Анализ на наличие лизилоксидазоподобных белков 2 и способы его применения
ATE462803T1 (de) Kit und verfahren zum nachweis von urothelkarzinom
WO2010099137A3 (en) In situ methods for monitoring the emt status of tumor cells in vivo
PE20160657A1 (es) Composiciones y metodos para identificar un riesgo de cancer en un sujeto
BR0317394A (pt) Uso de nicotinamida n-metiltransferase como um marcador para câncer colorretal
BR112014031958A2 (pt) bag3 como marcador de tecido e soro bioquímico
DK2118666T3 (da) Fremgangsmåde til normalisering af koncentrationen af analytter i en urinprøve
WO2011137388A3 (en) Identification and use of biomarkers for detection and quantification of the level of radiation exposure in a biological sample
ATE468535T1 (de) Verwendung von nnmt als marker für lungenkrebs
AR105379A1 (es) Dispositivo para detectar proteínas mal plegadas y sus métodos de uso
ES2845150T3 (es) Diagnóstico de pancreatitis aguda (PA) mediante la detección de glicoproteína 2 isoforma alfa (GP2A)
ATE545867T1 (de) I-plastin-testverfahren zur in-vitro-diagnose von kolorektalkarzinom
ATE426168T1 (de) Verwendung von asc als marker fur kolorektalkarzinome

Legal Events

Date Code Title Description
FC Refusal